Acuson’s stock falls after Q3 results

Article

Ultrasound company Acuson became the latest public company to pay the price for failing to meet Wall Street expectations. The company saw its share price shed 21% following release of flat third-quarter results and subsequent downgrades by several

Ultrasound company Acuson became the latest public company to pay the price for failing to meet Wall Street expectations. The company saw its share price shed 21% following release of flat third-quarter results and subsequent downgrades by several investment firms.

For the period (end-October), Mountain View, CA-based Acuson had revenues of $102.9 million, a 2.8% increase compared with the $100.1 million posted for the same quarter last year. Net income was $4.2 million, compared with $4.5 million reported in 1997. Earnings per share were unchanged from last year and were a penny below consensus Wall Street expectations. The news prompted the company’s stock to fall from $19.06 a share to $15 on Oct. 29, the day after the news was announced.

While pleased with growth in the firm’s U.S. and European businesses, chairman and CEO Samuel Maslak cited significant weakness in selected other international markets as adversely impacting the financial results. In recognition of continued volatility in international markets, Acuson is taking steps to adjust its business and keep expenses in line with current revenue outlook for the fourth quarter and 1999, Maslak said.

Recent Videos
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
Related Content
© 2025 MJH Life Sciences

All rights reserved.